Goodwin advised Ascenta Capital as an investor in the €400 million Series C financing of Munich biotech firm Tubulis.
Tubulis generates uniquely matched antibody-drug conjugates with superior biophysical properties that have demonstrated durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models and first clinical proof-of-concept in platinum-resistant ovarian cancer.
Ascenta Capital is a venture capital firm founded in 2023 that specializes in the biotechnology sector. The firm was born to help innovative companies as they translate from scientific foundations to clinical development of meaningful medicines for patients.
The Private Equity team was led by partner Sebastian Walczak and included counsel Silvio McMiken, associates Silvia Rava and Nadja Einwächter (all Munich) as well as partner Joseph Flynn (Boston).